The Lopinavir and ritonavir are antiviral drugs effectively utilized in combination to cure the human immunodeficiency virus (HIV). This amalgamation of drugs is utilized with other HIV medications to support the control of HIV disease. It simplifies to decrease the amount of HIV in the patient’s body so as the immune system can function well. This drug diminutions the unplanned of catching HIV complications (such as new infections, cancer) and improves the quality of life. The amalgamation of this drug belongs to a class of drugs well-known as HIV protease inhibitors.
According to the report analysis, ‘Global Lopinavir and Ritonavir Market to grow with a significant CAGR by 2026’ states that the effective augment in the cases of HIV patients is one of the prominent aspects participating in the market growth. For instance, the U.S. Department of Health & Human Services has projected that nearly 37.9 million people living with HIV in 2018 across the globe, and augment 8 million since 2010. Furthermore, the outbreak of COVID-19 and continuing clinical trials to test the efficiency of lopinavir and ritonavir in COVID-19 treatment is probable to generate a significant growth opportunity in the market over the review period.
For instance, in April 2020, researchers at the Jin Yin-Tan Hospital in China found that the mixture of the lopinavir-ritonavir HIV antivirals led to speedy symptom advancement in COVID-19 patients. However, the unwanted health effects limit the growth of the market over the estimated period of 2020-2026.
Major market players involved in this report are AbbVie Inc., Lannett Co Inc., Hikma Pharmaceuticals, Cipla Limited, Mylan N.V., Hetero Drugs, Aurobindo Pharma Ltd., Amneal Pharmaceuticals Inc., Rewine Pharmaceutical, and several others. Moreover, the players across the worldwide lopinavir and ritonavir market are effectively operating for leading the highest market growth and registering the effective value of market share around the globe while implementing the profitable strategies such as joint ventures, mergers, and acquisition, new product development, amalgamation, collaboration, and several others such as spreading the awareness connected to the applications, delivering better consumer satisfaction, decreasing the linked prices, employing the young workforce which further benefitted for obtaining the effective competitive edge and generating the effective percentage of revenue during the short span of time.
Although, the regional analysis of the worldwide Lopinavir and Ritonavir market is considered for the foremost regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the prominent region across the world in terms of market share due to effective augment in the government funding along with great incidences of HIV infection across the region. Whereas, the Asia-Pacific is also projected to exhibit the greatest growth rate / CAGR over the forecast duration of 2020-2026. Factors such as developing healthcare infrastructure, HIV epidemic would generate lucrative growth prospects for the Lopinavir and Ritonavir markets around the Asia-Pacific region. Therefore, in the near years, it is anticipated that the market of lopinavir and ritonavir will increase more effectively over the upcoming years.
For More Information on the Research Report, refer to the below links: –
Ankur Gupta, Head Marketing & Communications